Cook, G Kaufman, JL Usmani, SZ San-Miguel, J Bahlis, NJ White, D Benboubker, L Leiba, M Ho, PJ Kim, K others, Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma, 20--20, 2020,